CD274 and non-small cell lung carcinoma: Correspondingly, in our study, the median OS was 20.6 and 18.9 months for first-line PD-(L)1 inhibitor combination therapy in PS0-1 NSQ and SQ NSCLC (any PD-L1 expression).